» Articles » PMID: 32076030

Deregulated MicroRNAs in Neurofibromatosis Type 1 Derived Malignant Peripheral Nerve Sheath Tumors

Overview
Journal Sci Rep
Specialty Science
Date 2020 Feb 21
PMID 32076030
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant peripheral nerve sheath tumors (MPNST) are aggressive cancers that occur spontaneously (sporadic MPNST) or from benign plexiform neurofibromas in neurofibromatosis type 1 (NF1) patients. MPNSTs metastasize easily, are therapy resistant and are frequently fatal. The molecular changes underlying the malignant transformation in the NF1 setting are incompletely understood. Here we investigate the involvement of microRNAs in this process. MicroRNA expression profiles were determined from a series of archival, paired samples of plexiform neurofibroma and MPNST. Ninety differentially expressed microRNAs were identified between the paired samples. Three downregulated microRNAs (let-7b-5p, miR-143-3p, miR-145-5p) and two upregulated microRNAs (miR135b-5p and miR-889-3p) in MPNST were selected for functional characterization. In general, their differential expression was validated in a relevant cell line panel but only partly in a series of unpaired, fresh frozen tumor samples. As part of the validation process we also analyzed microRNA expression profiles of sporadic MPNSTs observing that microRNA expression discriminates NF1-associated and sporadic MPNSTs. The role of microRNAs in cancer progression was examined in NF1-derived MPNST cell lines by transiently modulating microRNA levels. Our findings indicate that some microRNAs affect migratory and invasive capabilities and Wnt signaling activity but the effects are distinct in different cell lines. We conclude that miRNAs play essential regulatory roles in MPNST facilitating tumor progression.

Citing Articles

A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for Treatment.

Xiao K, Yang K, Hirbe A Cancers (Basel). 2025; 17(2).

PMID: 39857962 PMC: 11763529. DOI: 10.3390/cancers17020180.


Biomarker Landscape in RASopathies.

Ferrito N, Baez-Flores J, Rodriguez-Martin M, Sastre-Rodriguez J, Coppola A, Isidoro-Garcia M Int J Mol Sci. 2024; 25(16).

PMID: 39201250 PMC: 11354534. DOI: 10.3390/ijms25168563.


A study of microRNAs as new prognostic biomarkers in anal cancer patients.

Dahl O, Myklebust M Acta Oncol. 2024; 63:456-465.

PMID: 38899393 PMC: 11332526. DOI: 10.2340/1651-226X.2024.27976.


miR-889-3p targeting BMPR2 promotes the development of retinoblastoma via JNK/MAPK/ERK signaling.

Gao Y, Du P Sci Rep. 2024; 14(1):7277.

PMID: 38538669 PMC: 10973389. DOI: 10.1038/s41598-023-49994-2.


Altered Expressions of NF1 and NF1-Related microRNAs as Biomarkers in the Diagnosis of Undifferentiated Pleomorphic Sarcoma.

Zhang P, Huang L, Ma P, Niu X Front Genet. 2022; 13:870191.

PMID: 35559021 PMC: 9086456. DOI: 10.3389/fgene.2022.870191.


References
1.
Ferner R, Gutmann D . Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol. 2013; 115:939-55. DOI: 10.1016/B978-0-444-52902-2.00053-9. View

2.
Gutmann D, Aylsworth A, Carey J, Korf B, Marks J, Pyeritz R . The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997; 278(1):51-7. View

3.
Carroll S, Ratner N . How does the Schwann cell lineage form tumors in NF1?. Glia. 2008; 56(14):1590-1605. PMC: 2652636. DOI: 10.1002/glia.20776. View

4.
Ratner N, Miller S . A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer. 2015; 15(5):290-301. PMC: 4822336. DOI: 10.1038/nrc3911. View

5.
Evans D, Baser M, McGaughran J, Sharif S, Howard E, Moran A . Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002; 39(5):311-4. PMC: 1735122. DOI: 10.1136/jmg.39.5.311. View